DUBLIN, Ireland – Elan Corp. plc has decided against spinning out its drug delivery arm, Elan Drug Technologies (EDT), into a separate business after concluding that "market conditions at this time are not conducive to an appropriate valuation." (BioWorld International)

Living up to its stock ticker (MOVE), Movetis NV has provided a rapid exit for its shareholders by attracting a €428 million (US$564.6 million) takeover bid from Shire plc, less than eight months after completing its IPO last December. (BioWorld International)